Evidence map›Paper›PMID 35756764›Full record

ArticleJournal of dental sciences2022

miR-509 inhibits cancer stemness properties in oral carcinomas via directly targeting PlK1.

Ming-Yi Lu, Chih-Yuan Fang, Pei-Ling Hsieh, Yi-Wen Liao, Lo-Lin Tsai, Cheng-Chia Yu

Open access · goldAbstract read
In one paragraph

Article in Journal of dental sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Ming-Yi LuSchool of Dentistry, Chung Shan Medical University, Taichung, Taiwan.
Chih-Yuan FangDivision of Oral and Maxillofacial Surgery, Department of Dentistry, Wan Fang Hospital, Taipei, Taiwan.
Pei-Ling HsiehDepartment of Anatomy, School of Medicine, China Medical University, Taichung, Taiwan.
Yi-Wen LiaoDepartment of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
Lo-Lin TsaiDivision of Oral and Maxillofacial Surgery, Department of Dentistry, Wan Fang Hospital, Taipei, Taiwan.
Cheng-Chia YuSchool of Dentistry, Chung Shan Medical University, Taichung, Taiwan.
Chung Shan Medical University · TWChina Medical University · TWChung Shan Medical University Hospital · TWLuodong Poh-Ai Hospital · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/purpose: Oral cancer is one of the common cancers worldwide. Emerging evidence has indicated that microRNAs (non-coding RNA molecules of approximately 22 nucleotides in length) are implicated in the regulation of cancer stemness. However, the functional role of microRNA-509 (miR-509) in the characteristics of oral cancer stem cells (CSCs) has not been unraveled. Materials and methods: The expression level of miR-509 in ALDH1 Results: We showed the expression of miR-509 was downregulated in the CSCs derived from oral cancer cells (SAS), and upregulation of miR-509 diminished the several CSCs features, including ALDH1 activity, self-renewal capacity, CD44 expression, migration, and colony-forming abilities. Moreover, the result from the luciferase reporter assay validated the direct binding of miR-509 to plk1. Conclusion: Our results suggest that the miR-509/plk1 axis may mediate the cancer stemness in oral cancer, and targeting this axis may attenuate the progression of oral cancer.

Indexed as

Cancer stem cellsMicroRNA-509Oral cancerPolo like kinase 1

Identifiers

PMID35756764
PMCPMC9201550
OpenAlexW3205866454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.